Overview

To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

Status:
Not yet recruiting

Trial end date:
2023-04-27

Target enrollment:

Participant gender:

Summary

The study is intended to assess the pharmacokinetics (PK), proprotein convertase subtilisin/kexin type 9 (PCSK9) reduction, safety and tolerabilityof AZD8233 in male and female participants with severe renal impairment and participants with ESRD compared to matched healthy control participants.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel